FlandersBio on Twitter

Follow us on Twitter

Archive for June 2014 - News

Archive for June 2014 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Blik op de resultaten van de wetgeving over scherpe voorwerpen: De Amerikaanse ervaring en de lessen voor Europa

30.06.2014

Dr. Kenneth Strauss - Endocrinoloog, Directeur van de veiligheid in geneeskunde, European Medical Association en Wereldwijd Medisch Directeur, BD. read more

TiGenix announces the clinical development of Cx611 in early rheumatoid arthritis and severe sepsis

30.06.2014

TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it will develop its intravenous-administered allogeneic stem cell product, Cx611, for patients suffering from early rheumatoid arthritis and for patients suffering from severe sepsis, a potentially life-threatening complication of infection. read more

ABLYNX KONDIGT EEN KAPITAALVERHOGING AAN VIA EEN PRIVATE PLAATSING VAN NIEUWE AANDELEN

30.06.2014

Ablynx [Euronext Brussel: ABLX] kondigt vandaag aan dat zij overgaat tot een private plaatsing van nieuwe aandelen bij institutionele investeerders met het doel om tot €30 miljoen aan bruto-opbrengsten op te halen. De Vennootschap kan dit bedrag mogelijks verhogen, maar het aantal aangeboden aandelen zal in geen geval meer dan 10% bedragen van het huidige aantal uitstaande en genoteerde aandelen (met name een maximum van 4.908.332 nieuwe aandelen). De Raad van Bestuur heeft besloten om het voorkeurrecht van de bestaande aandeelhouders op te heffen in het kader van deze transactie met betrekking tot de uitgifte van nieuwe aandelen, die zal plaatsvinden binnen de grenzen van het toegestaan kapitaal, zoals bepaald in de statuten van de Vennootschap en in overeenstemming met artikel 604 van het Belgisch Wetboek van Vennootschappen. read more

Over-activity of enzyme HDAC6 exacerbates symptoms of Amyotrophic Lateral Sclerosis

27.06.2014

​Scientists at VIB and KU Leuven have demonstrated in fruit-flies that over-activity of the enzyme HDAC6 in the nerve ends exacerbates the symptoms of the neurodegenerative condition Amyotrophic Lateral Sclerosis (ALS / Lou Gehrig’s Disease). Inhibition of this enzyme could offer a protective effect against ALS. read more

Celtic Renewables partners Bio Base Europe Pilot Plant following €1,5million investment

27.06.2014

Celtic Renewables, the Edinburgh-based biofuel company, has signed an agreement with Europe’s foremost biotechnology pilot facility to undergo next stage testing of its process to turn whisky by-products into biofuel that can power current vehicles. The partnership, which will allow the company to develop its technology at Bio Base Europe Pilot Plant (BBEPP) in Ghent, has been made possible by second round funding worth €1.5million, including more than €1million from the UK Government, to help meet its ambition of growing a new €125 million-a-year industry in the UK. read more

BIOCARTIS RECEIVES € 1,7M IWT GRANT FOR IMPROVED DISEASE DIAGNOSIS

27.06.2014

Biocartis announced today it received a grant of € 1.7M from the Flemish Government to further enhance the capabilities of its flagship platform Idylla™ (1). With this grant the Flemish Agency for Innovation by Science and Technology (IWT) affirms its belief in Biocartis’ cutting edge R&D. read more

New blood test identifies risk “Sudden Cardiac Death”

26.06.2014

UAntwerp (University of Antwerp), UZA (Antwerp University Hospital), and Multiplicom NV, a specialist in the development, production and commercialization of innovative molecular genetic tests, together developed a blood test to determine the genetic risk of “Sudden Cardiac Death” (SCD). This test, called PED MASTR, is already in use at the center of medical genetics of UZA/UAntwerp and will be launched worldwide from September 2014. read more

Bone Therapeutics Starts Patient Treatment in First Ever Clinical Trial with Allogeneic Bone Cell Therapy Product

25.06.2014

BONE THERAPEUTICS, the regenerative therapy company addressing unmet medical needs in the field of bone diseases and orthopaedics, today announces that the first patient has been treated with its novel allogeneic osteoblastic (bone-forming) cell therapy product ALLOB® in its phase I/IIa study for the treatment of delayed union fractures. read more

ThromboGenics Provides Update on Strategic Review Process

24.06.2014

In response to market rumors, ThromboGenics NV (Euronext Brussels: THR) today issues an update on the Strategic Review process that was initiated in February 2014. read more

Flanders at BIO 2014: service providers and investors joining us to San Diego

23.06.2014

Below you can find a selection of the Flemish investors and service providers traveling together with FlandersBio and Flanders Investment & Trade to San Diego for the BIO International Convention, the largest global event for the biotech industry (June 23-26, 2014). read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print